In a tissue microarray analysis from the AZURE trial, individuals with elevated DOCK4 levels in primary breast tumors showed markedly higher rates of bone recurrence than those with reduced DOCK4 expression. This evidence concerns the gene DOCK4 and breast neoplasm.